Clinical trials: Oncologic
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10…
- Trial name
- NCT02578732
- Testing
- FOLFOXA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Brown University
Autoimmune Diseases, Renal Disorders
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.
- Conditions
- Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
- Trial name
- NCT01210716
- Testing
- Therapeutic plasma exchange
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fenwal, Inc.
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Neuroblastoma
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed…
- Trial name
- NCT01313936
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Lung Cancer, Gastric Cancer
Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials
The purpose of this research study is to test a touchscreen computer program, which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials.
- Conditions
- Lung Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02020252
- Testing
- Testing an interactive technology in a diverse health literary population
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Chicago
Other Cancer, Gastrointestinal Cancer
Symptom Management Implementation of Patient Reported Outcomes in Oncology
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize…
- Conditions
- Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
- Trial name
- SIMPRO (NCT03850912)
- Testing
- Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview
- Where
- 6 sites in United States
- Volunteers
- 42,808 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Gynecologic Cancer
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic…
- Trial name
- NCT04503668
- Testing
- Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427 to continuing abiraterone acetate and prednisone treatment in men with metastatic castrate-resistant prostate cancer (MCRPC) who have…
- Conditions
- Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
- Trial name
- NCT01681433
- Testing
- OGX-427, Abiraterone Acetate, Prednisone
- Where
- 16 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Costantine Albany
Advanced Breast Cancer
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of…
- Trial name
- NCT00322348
- Testing
- Goserelin acetate
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Advanced Non-Small Cell Lung Cancer
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.
- Trial name
- NCT03516981
- Testing
- Pembrolizumab, Favezelimab, Lenvatinib
- Where
- 81 sites in United States, Australia and 14 more
- Volunteers
- 245 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Neoplasms
Targeted Fusion Biopsy of the Prostate
The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than…
- Trial name
- NCT02744534
- Testing
- FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Lung Cancer
Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung cancer kills 160,000 patients annually; this represents 28% of all US cancer deaths. The overall year survival rate has only improved from 12% to 17% in 33 years.
- Trial name
- NCT02123797
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Baptist Memorial Health Care Corporation
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate.
- Trial name
- NCT00216060
- Testing
- Risedronate
- Where
- 45 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Christopher Sweeney, MBBS
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Breast Cancer
Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients
To test the effect of an individualized exercise oncology program on healthcare utilization, 30-day hospital readmission, pain, and cancer treatment tolerance.
- Trial name
- NCT04106609
- Testing
- Supervised, individualized exercise oncology program, Current standard of care
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Karen Wonders